Land: Irland
Språk: engelska
Källa: HPRA (Health Products Regulatory Authority)
XYLAZINE BASE USP
Chanelle Pharmaceuticals Manufacturing Limited
QN05CM92
XYLAZINE BASE USP
10 %w/v
Solution for Injection
VPO-Vet.Practitioner Only
Equine - Food
Xylazine
Neurological Preparations
Authorised
1990-10-01
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Chanazine 10% Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Horses. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Chanazine 10% is a sedative with analgesic and muscle relaxant properties for use in horses only, in cases where sedation is required including: 1. Handling fractious animals e.g. for transportation 2. Medical examinations e.g. X-ray examinations, removal of bandages, examination of the penis and oral cavity. 3. Premedication for minor superficial operations, and local or regional anaesthesia. 4. Elimination of defaecation when examining and treating the vagina, uterus and hindquarters. 4.3 CONTRAINDICATIONS Do not administer by the intra-carotid route. Do not use in the first trimester or the last month of pregnancy. Do not use in cases of known hypersensitivity to the active ingredient. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. Each ml contains: Active Substance Xylazine Base 100 mg Excipients Methyl Parahydroxybenzoate 1.8 mg Propyl Parahydroxybenzoate 0.2 mg IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 02/10/2012_ _CRN 7012455_ _page number: 1_ 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Xylazine is not an ideal sedative for caesarean section because of its oxytoxic effect which impedes uterine suturing. The use of xylazine should be carefully considered in cases of cardiac aberrations, arterial hypotension/shock and renal or hepatic impairment. Careful consideration should also be given before administering to an Läs hela dokumentet